目标：胸膜积液是慢性髓细胞白血病（CML）患者使用达沙替尼治疗期间常见的不良事件。然而，亚洲CML患者的PE病理机制和适当的管理尚未阐明。本研究调查了亚洲CML患者使用达沙替尼治疗期间PE的发生率、风险和适当管理方法。方法：我们在CML合作研究组数据库中回顾性收集了接受一线达沙替尼治疗的CML慢性期患者的数据。患者：我们确定了89例患者中的44例PE，并分析了先前报道的PE风险因素和有效管理方法。结果：单因素分析显示，年龄、糖尿病、慢性肾衰竭、高血压、心血管事件史和达沙替尼剂量与PE显著相关。多因素分析显示，≥65岁的年龄是PE的唯一独立风险因素。相对于单一利尿剂的使用，达沙替尼剂量减少和转换到酪氨酸激酶抑制剂在有效减少PE体积上有显著差异。结论：虽然有待进一步研究，但我们的观察表明，年龄增长是PE的重要风险因素，而达沙替尼的剂量减少或替换可能是亚洲CML患者在真实世界临床实践中治疗PE的有效策略。

Objective Pleural effusion (PE) is a common adverse event that occurs during dasatinib therapy for chronic myeloid leukemia (CML). However, the pathomechanism of PE and appropriate management of Asian patients with CML have not been elucidated. This study investigated the incidence rate, risk, and appropriate management of PE in Asian patients with CML treated with dasatinib. Methods We retrospectively collected data on patients in the chronic phase of CML who received first-line dasatinib therapy and were registered in the CML-Cooperative Study Group database. Patients We identified 44 cases of PE in a series of 89 patients and analyzed previously reported risk factors and effective management of PE. Results A univariate analysis revealed that age, diabetes mellitus, chronic renal failure, hypertension, the history of cardiovascular events, and dasatinib dose were significantly associated with PE. A multivariate analysis revealed that age ≥65 years old was the only independent risk factor for PE. Dasatinib dose reduction and switching to a tyrosine kinase inhibitor showed a statistically significant difference in effectively reducing PE volume compared to single diuretic use. Conclusion Although further studies are warranted, our observations showed that advanced age is a significant risk factor for PE, and tyrosine kinase inhibitor dose reduction or replacement of dasatinib may be an effective management strategy for PE in Asian CML patients who received first-line treatment with dasatinib in real-world clinical practice.